Shares of Health Care sector company Moderna moved -0.2% today, and are now trading at a price of $109.95. The large-cap stock's daily volume was 6,004,009 compared to its average volume of 3,254,514. The S&P 500 index returned a -0.0% performance.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company is based in Cambridge and has 3,900 full time employees. Its market capitalization is $41,913,925,632.
16 analysts are following Moderna and have set target prices ranging from $74.49 to $390.63 per share. On average, they have given the company a rating of buy. At today's prices, MRNA is trading -40.14% away from its average analyst target price of $183.68 per share.
Over the last year, MRNA shares have gone down by -43.0%, which represents a difference of -53.0% when compared to the S&P 500. The stock's 52 week high is $217.25 per share and its 52 week low is $108.26. With average free cash flows of $5.24 Billion that have been growing at an average rate of 92.0% over the last 4 years, Moderna declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cashflow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-24 | 4,981,000 | -400,000 | 5,381,000 | -61.3 |
| 2022-02-25 | 13,620,000 | -284,000 | 13,904,000 | 563.68 |
| 2021-02-26 | 2,027,000 | -68,000 | 2,095,000 | 590.63 |
| 2020-02-27 | -459,000 | -32,000 | -427,000 | n/a |
